Indivior Pharmaceuticals
INDV
76 hedge funds and large institutions have $1.91B invested in Indivior Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
27% more funds holding
Funds holding: 60 → 76 (+16)
4.46% more ownership
Funds ownership: 44.95% → 49.41% (+4.5%)
3% more capital invested
Capital invested by funds: $1.86B → $1.91B (+$55.8M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$49.4M |
| 2 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
+$45.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.7M |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
+$21.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$8.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$29.2M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.77M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.88M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$3.85M |
| 5 |
JP Morgan Chase
New York
|
-$3.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
76
IFP Advisors
Tampa,
Florida
| $23 | – | – | – |
|
|
SCM
77
Soleus Capital Management
Greenwich,
Connecticut
| – | -$443K | -18,624 | Closed |
|
78
Fidelity International
Hamilton,
Bermuda
| – | -$427K | -18,444 | Closed |
|
|
O
79
Ossiam
Paris,
France
| – | -$288K | -12,426 | Closed |
|
80
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$595 | -25 | Closed |
|
INDV Hedge Fund Activity: Q3 2023 in Review
76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q3 2023, worth a combined $1.91B — up 3% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new INDV positions and 4 closed out — a net gain of 16 holders — while 18 added to existing stakes and 23 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $49.4M. The largest seller was Scopia Capital Management, cutting an estimated $29.2M.
- 76 institutional investors held Indivior Pharmaceuticals (INDV) as of Q3 2023, up from 60 in Q2 2023.
- Funds reported $1.91B of Indivior Pharmaceuticals stock for Q3 2023, up 3% quarter-over-quarter.
- 20 funds opened new Indivior Pharmaceuticals positions in Q3 2023 and 4 closed out, a net change of +16 holders.
- The largest Indivior Pharmaceuticals buyer in Q3 2023 was Goldman Sachs, an estimated $49.4M added.
- The largest Indivior Pharmaceuticals seller in Q3 2023 was Scopia Capital Management, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2023.